Under its new Parkinson's Disease Biomarker Program, the National Institute of Neurological Disorders and Stroke has funded nine research teams, most of which involve proteomic approaches, to attempt to identify biomarkers that could be used as either predictive or prognostic tools in the care of PD patients.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.